News Release

The Lancet Haematology: Global inequalities in survival for childhood leukaemia persist, highlighting need for better care

Peer-Reviewed Publication

The Lancet

Although global inequalities in survival from childhood leukaemia have narrowed, they still persist with five-year survival in some countries nearly twice as high as in others for children diagnosed during 2005-2009, according to a study published in The Lancet Haematology.

While survival has increased in many countries, five-year survival for acute lymphoblastic leukaemia (ALL) in Germany was 92%, compared to 52% in Colombia for children diagnosed in 2005-2009. Additionally, the study finds that survival has improved for most age groups, but it remains lowest for infants under 1.

According to the latest data on global childhood cancer incidence, also published today in The Lancet Oncology, leukaemia is the most common cancer in children aged 0-14 years old worldwide - accounting for a third of cancer cases in 0-9 year olds, and a quarter of cases in 10-14 year olds.

The authors of the study on survival used individual patient data for almost 90000 children, provided by 198 cancer registries in 53 countries. They estimated survival for the two most common types of childhood leukaemia, acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), and for other less common blood cancers.

Taking into account the differences in age and the risk of death from other causes between countries and regions, the researchers found that five-year survival from childhood ALL and AML increased in most countries between 1995 and 2009. However, there were wide international inequalities.

Overall, ALL survival was the highest - with the probability of surviving at least five years ranging from 11% (in China) to 87% (Austria) for children diagnosed between 1995 and 1999. The range narrowed to 52% (Colombia) and 92% (Germany) for children diagnosed between 2005 and 2009.

There was significant progress in five-year survival for AML, but it remained lower than for ALL - increasing from between 4% (China) and 72% (Sweden) for those diagnosed between 1995 and 1999, to between 33% (Bulgaria) and 78% (Germany) for children diagnosed between 2005 to 2009. This is likely to be the result of recent improvements in diagnosis and treatment.

The authors highlight that in some countries, such as Germany and Austria, survival for ALL and AML has consistently been high compared to other nations, which might be due to closer adherence to treatment protocols.

Between 1995-1999 and 2005-2009, five-year survival for childhood ALL increased from 79% to 89% in the UK, and from 83% to 88% in the US. For AML, five-year survival increased from 59% to 68% in the UK and from 52% to 63% in the US. Survival in China increased substantially over the same period - from 11% to 69% for ALL survival, and 4% to 41% for AML survival.

The chances of survival depended on the child's age when diagnosed with leukaemia. Overall, children aged 1-9 years old at diagnosis had higher survival for both types of leukaemia than those aged 10-14 years old or less than 1 year. Survival has improved for most age groups, for both ALL and AML, especially for children diagnosed with ALL aged 10-14 years. It is still lowest for children diagnosed in the first year of life.

"There is room for improvement in the management of childhood leukaemia in many countries," said lead author Dr Audrey Bonaventure, London School of Hygiene & Tropical Medicine, UK. "These findings show the extent of worldwide inequalities in access to optimal health care for children with cancer. Survival for children with ALL can be as high as 90% at five years after diagnosis, and up to 80% for children with AML, but in some countries, survival remains below 60% for both diseases. We do not yet know how to prevent leukaemia in children, but optimal treatment offers the chance of long-term survival for most children. Providing additional resources, alongside evidence-based initiatives such as international collaborations and treatment guidelines, could improve access to efficient treatment and care for all children with leukaemia. This would contribute substantially to reducing worldwide inequalities in survival." [1]

The study had limitations in some countries as a result of small numbers of patients and limited data collection. For example, in some low- and middle-income countries, the data were sparse, such that survival estimates could not be age-standardised, limiting the interpretation of survival trends.

Writing in a linked Comment, Professor Philippe Autier, University of Strathclyde Institute of Global Public Health at the International Prevention Research Institute, France, said: "These improvements are essentially due to the combined effects of many factors including the increasing precision in diagnosis and the substantial progress in the management of children with cancer, including supportive care provided to children and their families. However, the accomplishment of 5-year net survival of around 80% in many high-income countries should not distract from the dire reality that about 80% of leukaemia cases in children occur in low-income and middle-income countries where there is little access to the sophisticated and costly specialised medical resources required for the optimum management of these conditions. From a worldwide perspective, it is the adoption by low- and middle-income countries of affordable, locally adapted, multidisciplinary management programmes that is likely to translate into the largest gains in survival for children with haematological cancer."



The study was funded by Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research Foundation, Swiss Cancer League and the University of Kentucky. It was conducted by scientists from the London School of Hygiene & Tropical Medicine (UK), Public Health England (UK), Fondazione IRCCS Istituto Nazionale dei Tumori (Italy), National Registry of Childhood Haematopoietic Malignancies, INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité (France), Umtata University (South Africa), Girona Cancer Registry, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology-Girona (Spain), Registro Español de Tumores Infantiles, UVEG (Spain), International Agency for Research on Cancer (France), Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern (Switzerland), the University of Oxford (UK) and the CONCORD Working Group. [1] Quote direct from author and cannot be found in the text of the Article.


The Lancet Oncology

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.